Immatics N.V.

Immatics Biotechnologies GmbH

General information
Immatics N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany

Contact person: Harpreet Singh, Chief Executive Officer
Company main phone: +49 (7071) 53970
Company main fax:  +49 (7071) 5397900
Website:  https://www.immatics.com
Year founded:2000
Source of foundation:Spin-off from university
Name of foundation source:H.G. Rammensee's laboratory at the University of Tübingen, Germany
No. of employees: Worldwide:  432
Corporate description / mission:
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company is developing targeted TCR-based immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) consisting of autologous (ACTengine®) or allogeneic (ACTallo®) product classes and antibody-like TCR Bispecifics, also called T cell Engaging Receptors (TCER®).
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2020
Remarks on ownership / listings
In July 2020, Immatics started trading on NASDAQ as a result of a business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA; or “Arya”), a special purpose acquisition, sponsored by Perceptive Advisors.

In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston Texas.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Cell therapy
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • In-licensing
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:7
Phase I:4
Phase II:1
Description of products:
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.
Special IP situation:
The XPRESIDENT technology is protected by granted patents and patent applications.
Technology used:
XPRESIDENT™
XCEPTOR®
Financing details
Fiscal year (end of) 2023
Revenues:USD 58.42M
R&D expenses:USD 128.39M
Cash:USD 236.39M
Total liabilities:USD 308.24M
No. of shares:103'053'000
Market cap. / valuation:USD 1'308.77M
Collaborations & Clients
Partnering strategy / collaborations:
Amgen
MDACC
MorphoSys
Roche
Genmab
X